Oragenics, Inc. (OGEN)

NYSEAMERICAN: OGEN · IEX Real-Time Price · USD
1.430
-1.020 (-41.63%)
Feb 28, 2024, 2:26 PM EST - Market open
-41.63%
Market Cap 9.73M
Revenue (ttm) 37,653
Net Income (ttm) -10.15M
Shares Out 3.08M
EPS (ttm) -4.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,386,733
Open 1.370
Previous Close 2.450
Day's Range 1.340 - 1.450
52-Week Range 1.340 - 7.740
Beta 0.38
Analysts n/a
Price Target n/a
Earnings Date Apr 15, 2024

About OGEN

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. f... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 6
Stock Exchange NYSEAMERICAN
Ticker Symbol OGEN
Full Company Profile

Financial Performance

In 2022, Oragenics's revenue was $131,521, an increase of 51.20% compared to the previous year's $86,987. Losses were -$14.29 million, -9.06% less than in 2021.

Financial Statements

News

Oragenics Announces Pricing of Public Offering

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...

17 hours ago - Business Wire

Oragenics Announces Proposed Public Offering

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment...

21 hours ago - Business Wire

Oragenics, Inc. Announces Leadership Transition

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurologica...

15 days ago - Business Wire

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod...

21 days ago - Business Wire

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod...

23 days ago - Business Wire

Oragenics Announces Termination of At-The-Market Offering Program

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has terminated its previously announced “at-the-market” (“ATM”) equity offering pr...

5 weeks ago - Business Wire

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of assets related to Odyssey Health, ...

2 months ago - Business Wire

Oragenics Issues Update to Shareholders

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN): Fellow Shareholders, As our annual meeting date approaches and in response to valuable feedback from our shareholders, I believe it...

4 months ago - Business Wire

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

LAS VEGAS, NV / ACCESSWIRE / October 18, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products is p...

Other symbols: ODYY
4 months ago - Accesswire

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective Oct...

4 months ago - Business Wire

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

TAMPA, Fla. & LAS VEGAS--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY) (“Odyssey”) announce the signing of a definitive a...

5 months ago - Business Wire

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a material...

5 months ago - Business Wire

Oragenics, Inc. Announces Private Placement

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced i...

7 months ago - Business Wire

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, announces the award of a grant fr...

9 months ago - Business Wire

Oragenics to Participate in the World Vaccine Congress Washington

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that...

1 year ago - Business Wire

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings ...

1 year ago - Business Wire

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the ...

1 year ago - Business Wire

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that...

1 year ago - Business Wire

Oragenics, Inc. Regains Compliance with NYSE American

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

1 year ago - Business Wire

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

1 year ago - Business Wire

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announ...

1 year ago - Business Wire

Oragenics, Inc. Receives NYSE American Notice

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

1 year ago - Business Wire

Oragenics, Inc. Announces New Chair

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced th...

1 year ago - Business Wire

Oragenics Issues Letter to Shareholders

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued th...

1 year ago - Business Wire